Products & ReviewLife Sciences
Carterra LSA-XT
Disruptive Technology for Screening and Characterization. Enhanced sensitivity and fast data collection rate build upon unmatched capabilities in throughput and enable assays such as TPDs/PROTAC®s, kinase, cytokines, DELs, and protein:protein inhibitors.
Request Pricing
Receive your quote directly from the manufacturer.
The proprietary Carterra LSAXT HT-SPR technology platform expands beyond antibody discovery to enable PROTAC®s, protein-protein inhibitors, kinase, and cytokine screening and characterization. The LSAXT delivers up to 100x the data in 10% of the time and with 1% of the sample requirements of other systems and consumable costs of other label-free instruments.
The LSAXT enables the following automated workflows in single unattended runs:
- Capture-based kinetics and affinity: Screen up to 1152 ligands
- Coupled kinetics: Up to 384 immobilized ligands
- Epitope binning: Interrogate up to 384×384 pairwise, competitive interactions
- Quantitation: Measure concentration of up to 1152 samples
- Peptide mapping: Screen up to 384 analytes against an array of up to 384 peptides
- Blocking / neutralization assays: 384 assay capacity
- Regeneration scouting: Scout 96 conditions in parallel
- General multiplexed applications: Array any combination of up to 384 ligands
